AirSculpt Technologies, Inc. - Common Stock (AIRS)
1.7600
-0.0400 (-2.22%)
NASDAQ · Last Trade: Sep 30th, 4:58 PM EDT
Detailed Quote
Previous Close
1.800
Open
1.840
Bid
1.730
Ask
1.790
Day's Range
1.680 - 1.850
52 Week Range
1.510 - 12.00
Volume
1,131,240
Market Cap
97.93M
PE Ratio (TTM)
-6.286
EPS (TTM)
-0.3
Dividend & Yield
N/A (N/A)
1 Month Average Volume
916,259
Chart
About AirSculpt Technologies, Inc. - Common Stock (AIRS)
Airsculpt Technologies Inc is a pioneering company specializing in minimally invasive body contouring procedures. The company has developed a unique technique that aims to provide patients with a more refined and effective option for fat removal and body sculpting, distinguishing itself in the competitive aesthetic market. Through a proprietary approach that emphasizes precision and safety, Airsculpt Technologies focuses on enhancing patient satisfaction and outcomes while advancing the field of cosmetic surgery. With a commitment to innovation and quality care, the company seeks to redefine body aesthetics for its clientele. Read More
NEW YORK, Sept. 29, 2026 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of AirSculpt Technologies, Inc. (“AirSculpt” or the “Company”) (NASDAQ: AIRS). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980.
NEW YORK, Sept. 22, 2026 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of AirSculpt Technologies, Inc. (“AirSculpt” or the “Company”) (NASDAQ: AIRS). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980.
Schall, Brown & Schwartz LLP (“SBS”), a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of AirSculpt Technologies, Inc. (“AirSculpt” or “the Company”) (NASDAQ: AIRS) for violations of the securities laws.
NEW YORK, Sept. 15, 2026 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of AirSculpt Technologies, Inc. (“AirSculpt” or the “Company”) (NASDAQ: AIRS). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980.
NEW YORK, Sept. 08, 2026 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of AirSculpt Technologies, Inc. (“AirSculpt” or the “Company”) (NASDAQ: AIRS). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980.
NEW YORK, Sept. 01, 2026 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of AirSculpt Technologies, Inc. (“AirSculpt” or the “Company”) (NASDAQ: AIRS). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980.
AirSculpt Technologies (NASDAQ:AIRS) is seeing stabilization in its core body-contouring business after several quarters of declines, while expanding services aimed at patients using GLP-1 weight-loss drugs, Chief Executive Officer Yogi Jashnani said at a Canaccord consumer conference.
The company
AirSculpt Technologies (NASDAQ:AIRS) reported second-quarter revenue of $42.9 million, down 2.5% from the prior-year period, as the company cited stable revenue trends, positive same-center case growth and continued investment in marketing and expanded procedure offerings.
Chief Executive Officer Y
MIAMI BEACH, Fla., May 27, 2026 (GLOBE NEWSWIRE) -- AirSculpt Technologies, Inc. (“AirSculpt” or the “Company”) (NASDAQ: AIRS), an industry leader and provider of premium body contouring procedures, today announced that the Company will participate in upcoming investor conferences.
AirSculpt Technologies (NASDAQ:AIRS) executives said the body contouring company has returned to same-store sales growth after more than two years of declines, while outlining plans to expand services tied to GLP-1 weight-loss drug side effects and eventually resume clinic growth across the U.S.
Ch
AirSculpt Technologies (NASDAQ:AIRS) reported first-quarter fiscal 2026 results that management characterized as a “key turning point,” citing stabilized revenue, the first positive same-center sales result in more than two years, and continued debt reduction.
Q1 results: flat revenue, positive sam
MIAMI BEACH, Fla., April 06, 2026 (GLOBE NEWSWIRE) -- In a release issued under the same headline on April 2nd, 2026, by AirSculpt Technologies, Inc. (NASDAQ:AIRS), please note that the Company determined that a one-time non-cash adjustment related to the closure of its London facility was inaccurate in the calculation of Adjusted EBITDA, Adjusted EBITDA Margin, and Adjusted Net (Loss)/Income. The updated release reflects the updated figures.
MIAMI BEACH, Fla., April 02, 2026 (GLOBE NEWSWIRE) -- AirSculpt Technologies, Inc. (NASDAQ:AIRS)(“AirSculpt” or the “Company”), a national provider of premium body contouring procedures, today announced results for the fourth quarter and twelve months ended December 31, 2025.
